1. 66P Real-world data of first-line chemo-immunotherapy for patients with extensive stage SCLC: A multicentre experience from Switzerland and the UK. (December 2022) Authors: Moliner, L.; Zellweger, N.M.; Schmidt, S.M.; Waibel, C.; Froesch, P.R.; Häuptle, P.; Blum, V.; Holer, L.; Frueh, M.; Bhagani, S.; Gray, H-L.J.; Cox, S.; Khalid, T.; Scott, D.C.; Robinson, S.D.; Hennah, L.; Handforth, C.; Mauti, L.A.; Califano, R.; Rothschild, S.I. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. Issue 10 (8th May 2018) Authors: Martinello, M.; Bhagani, S.; Gane, E.; Orkin, C.; Cooke, G.; Dore, G. J.; Petoumenos, K.; Applegate, T. L.; Tu, E.; Marks, P.; Pagani, N.; Grebely, J.; Nelson, M.; Matthews, G. V. Journal: Journal of viral hepatitis Issue: Volume 25:Issue 10(2018) Page Start: 1180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗